At page 8, replace the paragraph beginning on line 19 with the following new paragraph:

A2

Figure 12 (SEQ ID NOS 86-89, respectively) provides the final consensus DNA sequence of the heavy and light chain variable regions.

At page 71, at the end of the specification, before the claims, delete the previously filed Sequence Listing and insert the printed Sequence Listing submitted herewith.

IN THE CLAIMS:

Please renumber claim pages 122-129 sequentially after the Sequence Listing submitted concurrently herewith.

Please cancel claim 1 and add new claims 32-44 as follows:

A3

32. A method for treating or preventing an infection caused by Gram positive bacteria in a patient comprising administering to the patient a therapeutically or prophylactively effective amount of a pharmaceutical composition,

wherein the pharmaceutical composition comprises an antibody to lipoteichoic acid of Gram positive bacteria, or fragment, region, or derivative thereof, and a pharmaceutically acceptable carrier, and

wherein the antibody, fragment, region, or derivative thereof

(a) binds to lipoteichoic acid at a level that is twice background or greater, and

(b) enhances the opsonization of Gram positive bacteria by 75% or more.

Sub C1

33. The method of claim 32, wherein the antibody is a monoclonal antibody.

34. The method of claim 33, wherein the monoclonal antibody is MAB 96-110.

35. The method of claim 34, wherein MAB 96-110 is chimeric and humanized.

LAW OFFICES
INNEGAN, HENDERSON, FARABOW, GARRETT, & DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

36. The method of claim 32, wherein the antibody, fragment, region, or derivative thereof binds to a peptide sequence chosen from:

W R M Y F S H R H A H L R S P (SEQ ID NO: 1) and

W H W R H R I P L Q L A A G R (SEQ ID NO: 2).

37. A method for treating or preventing an infection caused by Gram positive bacteria in a patient comprising administering to the patient a therapeutically or prophylactively effective amount of a pharmaceutical composition,

wherein the pharmaceutical composition comprises an antibody to lipoteichoic acid of Gram positive bacteria, or fragment, region, or derivative thereof, and a pharmaceutically acceptable carrier, and

wherein the antibody, fragment, region, or derivative thereof bind to a peptide sequence chosen from:

W R M Y F S H R H A H L R S P (SEQ ID NO: 1) and

W H W R H R I P L Q L A A G R (SEQ ID NO: 2).

38. The method of claim 37, wherein the antibody is a monoclonal antibody.

39. The method of claim 38, wherein the monoclonal antibody is MAB 96-110.

40. The method of claim 39, wherein MAB 96-110 is chimeric and humanized.

41. A method for treating or preventing an infection caused by Gram positive bacteria in a patient comprising administering to the patient a therapeutically or prophylactively effective amount of a pharmaceutical composition,

wherein the pharmaceutical composition comprises a lipoteichoic acid epitope peptide mimic, and a pharmaceutically acceptable carrier, and

wherein the peptide mimic is a peptide sequence chosen from:

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

(a) W R M Y F S H R H A H L R S P (SEQ ID NO: 1);

(b) W H W R H R I P L Q L A A G R (SEQ ID NO: 2); and

(c) peptide sequences that are substantially homologous to the sequences of (a) or (b).

42. A method for treating or preventing an infection caused by Gram positive bacteria in a patient comprising administering to the patient a therapeutically or prophylactively effective amount of a pharmaceutical composition,

wherein the pharmaceutical composition comprises a peptide encoded by DNA of the variable region of the anti-lipoteichoic acid antibody of Figure 12, or by a sequence that is at least 70% homologous to that DNA, and a pharmaceutically acceptable carrier.

43. A method for treating or preventing an infection caused by Gram positive bacteria in a patient comprising administering to the patient a therapeutically or prophylactively effective amount of a pharmaceutical composition,

wherein the pharmaceutical composition comprises a peptide characterized by amino acids corresponding to one or more of the Complementarity Determining Regions of the variable regions of the anti-lipoteichoic acid antibody of Figure 12, or amino acids that are at least 70% homologous to the Complementarity Determining Regions.

44. The method of claim 43, wherein the Complementarity Determining Regions are derived from MAB 96-110.

IN THE DRAWINGS:

Subject to the approval of the Examiner, please replace the current Figure 12 with the attached substitute Figure 12.

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000